FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281405> ?p ?o ?g. }

• W4379281405 endingPage "e19080" @default.
• W4379281405 startingPage "e19080" @default.
• W4379281405 abstract "e19080 Background: Polycythemia Vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production. Most patients (pts) harbor a JAK2 mutation and must have erythrocytosis or elevated red cell mass for diagnosis (DX). Pts are at increased risk of thrombosis. Current treatments include aspirin, therapeutic phlebotomy (TP), and cytoreductive therapy such as hydroxyurea (HU). In 2014, based on the RESPONSE study, ruxolitinib (rux), a selective JAK inhibitor, was approved for second line treatment after intolerance or inadequate response to HU. A recent real-world analysis of rux in PV showed durable hematocrit (HCT) control and decreased need for TP (Coltoff 2020). Despite emerging clinical reports, real-world data on HCT control, dose adjustment, and thrombotic risk with rux are extremely limited. Methods: A retrospective chart review from three centers was performed to evaluate PV pts treated with rux between Dec 2014 and Dec 2019. Pts age <18 at rux start, who received rux through investigational studies, and/or who had myelofibrosis were excluded. Data cutoff was May 30, 2022. Results: 69 patients were identified. Median time from PV DX to rux start was 4.4 yrs (range 0.1 to 40.2), and median follow-up from start of rux was 3.3 yrs (range 0.1 to 6.3). Pt characteristics: 37 (54%) Male, 59 pts (86%) White, 4 (6%) Black, and 64 (93%) Non-Hispanic. The most common reasons for starting rux were HU intolerance (46%), uncontrolled platelet count (28%), and symptom burden (19%). Median time on rux was 2.4 yrs (range 0.1 to 6.3); 43 pts (62%) remained on rux at data cutoff. A total of 6 pts (9%) received less than 3 months of rux before discontinuation, 8 pts (12%) received less than 6 months of rux. 41% pts (27/66), did not have HCT control (HCT <45%) within 1 month prior to rux start. Of evaluable pts, HCT control rates at 3 and 6 months were 88% (52/59) and 89% (47/53) respectively. Phlebotomy frequency in the 3-month periods before and after rux start were known for 48 pts; 21 (44%) experienced a decrease in phlebotomies within 3 months after initiation of rux, 20 (42%) remained stable, and 7 (16%) saw an increase (ranging from +1 to +3). Twelve pts (17%) required dose reductions/suspensions due to cytopenias. One pt experienced an acute pulmonary embolism while on rux (4.4 yrs after rux initiation). The pt was diagnosed with T cell lymphoma while on rux and the thrombotic event was attributed to lymphoma. This pt achieved HCT control on rux at 3 and 6 months. No arterial thromboses were observed. Conclusions: In this real-world analysis, rux was highly effective in controlling HCT in the vast majority of PV pts by 3 and 6 months. PV pts treated with rux rarely developed thrombosis. Rux was well tolerated, and few patients required dose reduction or discontinuation. [Table: see text]" @default.
• W4379281405 created "2023-06-05" @default.
• W4379281405 creator A5006044740 @default.
• W4379281405 creator A5006796378 @default.
• W4379281405 creator A5015755664 @default.
• W4379281405 creator A5019444571 @default.
• W4379281405 creator A5023092695 @default.
• W4379281405 creator A5035817509 @default.
• W4379281405 creator A5039057642 @default.
• W4379281405 creator A5042176968 @default.
• W4379281405 creator A5042992484 @default.
• W4379281405 creator A5047181107 @default.
• W4379281405 creator A5047723343 @default.
• W4379281405 creator A5059850025 @default.
• W4379281405 creator A5066072212 @default.
• W4379281405 creator A5067521829 @default.
• W4379281405 creator A5078207811 @default.
• W4379281405 creator A5078844706 @default.
• W4379281405 creator A5083860929 @default.
• W4379281405 creator A5085211731 @default.
• W4379281405 creator A5092083299 @default.
• W4379281405 date "2023-06-01" @default.
• W4379281405 modified "2023-09-23" @default.
• W4379281405 title "Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib." @default.
• W4379281405 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e19080" @default.
• W4379281405 hasPublicationYear "2023" @default.
• W4379281405 type Work @default.
• W4379281405 citedByCount "0" @default.
• W4379281405 crossrefType "journal-article" @default.
• W4379281405 hasAuthorship W4379281405A5006044740 @default.
• W4379281405 hasAuthorship W4379281405A5006796378 @default.
• W4379281405 hasAuthorship W4379281405A5015755664 @default.
• W4379281405 hasAuthorship W4379281405A5019444571 @default.
• W4379281405 hasAuthorship W4379281405A5023092695 @default.
• W4379281405 hasAuthorship W4379281405A5035817509 @default.
• W4379281405 hasAuthorship W4379281405A5039057642 @default.
• W4379281405 hasAuthorship W4379281405A5042176968 @default.
• W4379281405 hasAuthorship W4379281405A5042992484 @default.
• W4379281405 hasAuthorship W4379281405A5047181107 @default.
• W4379281405 hasAuthorship W4379281405A5047723343 @default.
• W4379281405 hasAuthorship W4379281405A5059850025 @default.
• W4379281405 hasAuthorship W4379281405A5066072212 @default.
• W4379281405 hasAuthorship W4379281405A5067521829 @default.
• W4379281405 hasAuthorship W4379281405A5078207811 @default.
• W4379281405 hasAuthorship W4379281405A5078844706 @default.
• W4379281405 hasAuthorship W4379281405A5083860929 @default.
• W4379281405 hasAuthorship W4379281405A5085211731 @default.
• W4379281405 hasAuthorship W4379281405A5092083299 @default.
• W4379281405 hasConcept C126322002 @default.
• W4379281405 hasConcept C141071460 @default.
• W4379281405 hasConcept C2776112149 @default.
• W4379281405 hasConcept C2778837598 @default.
• W4379281405 hasConcept C2780007613 @default.
• W4379281405 hasConcept C2780076729 @default.
• W4379281405 hasConcept C2780829020 @default.
• W4379281405 hasConcept C2780959883 @default.
• W4379281405 hasConcept C2781057849 @default.
• W4379281405 hasConcept C2781107747 @default.
• W4379281405 hasConcept C71924100 @default.
• W4379281405 hasConcept C90924648 @default.
• W4379281405 hasConceptScore W4379281405C126322002 @default.
• W4379281405 hasConceptScore W4379281405C141071460 @default.
• W4379281405 hasConceptScore W4379281405C2776112149 @default.
• W4379281405 hasConceptScore W4379281405C2778837598 @default.
• W4379281405 hasConceptScore W4379281405C2780007613 @default.
• W4379281405 hasConceptScore W4379281405C2780076729 @default.
• W4379281405 hasConceptScore W4379281405C2780829020 @default.
• W4379281405 hasConceptScore W4379281405C2780959883 @default.
• W4379281405 hasConceptScore W4379281405C2781057849 @default.
• W4379281405 hasConceptScore W4379281405C2781107747 @default.
• W4379281405 hasConceptScore W4379281405C71924100 @default.
• W4379281405 hasConceptScore W4379281405C90924648 @default.
• W4379281405 hasFunder F4320317544 @default.
• W4379281405 hasIssue "16_suppl" @default.
• W4379281405 hasLocation W43792814051 @default.
• W4379281405 hasOpenAccess W4379281405 @default.
• W4379281405 hasPrimaryLocation W43792814051 @default.
• W4379281405 hasRelatedWork W2007651804 @default.
• W4379281405 hasRelatedWork W2088272024 @default.
• W4379281405 hasRelatedWork W2111123136 @default.
• W4379281405 hasRelatedWork W2547696146 @default.
• W4379281405 hasRelatedWork W2578330526 @default.
• W4379281405 hasRelatedWork W2903749170 @default.
• W4379281405 hasRelatedWork W2981391579 @default.
• W4379281405 hasRelatedWork W3030576992 @default.
• W4379281405 hasRelatedWork W3129381400 @default.
• W4379281405 hasRelatedWork W4377205932 @default.
• W4379281405 hasVolume "41" @default.
• W4379281405 isParatext "false" @default.
• W4379281405 isRetracted "false" @default.
• W4379281405 workType "article" @default.